Русский
English
عربي
Eipico
EIPICO was established in Tenth of Ramadan City in 1980, with a capital of EGP 7 Million, currently raised to EGP 1500 Million, as an Egyptian public shareholder company operating according to the Investment Law (No. 43/1974 modified by Law No. 32/1977).
EIPICO started production in 1985 as the Leading Company in Egypt and in the Middle East and North Africa (MENA) Region, to produce pharmaceutical products according to Good Manufacturing Practice (G.M.P.) regulations, with the aim of providing local and international markets with high-quality products at affordable prices.
EIPICO has 2 Plants built over a surface area of 120,000 m2, which fully operate in compliance with cGMP regulations, to assure the safety and efficacy of the pharmaceutical products.
EIPICO is unique with its 9 Sterile Products Areas, which are the Largest and the Most Advanced, in Egypt and in the Middle East and North Africa (MENA) Region.
EIPICO has the First Biotechnology and Genetic Engineering Research Center in Egypt manufacturing biopharmaceutical products.
EIPICO manufactures More than 400 Pharmaceutical Products covering 25 Therapeutic Groups.
EIPICO is currently constructing EIPICO 3 factory , on 10,500 square It will be designated for Biological & Biosimilar products and A new state of the art Modular Manufacturing Facility
EIPICO 3 will be the first of its kind in Egypt and in the MENA Region, to manufacture Biosimilar & Biological products from the Cell Line all the way through Upstream & Downstream Process to reach Drug Substance as well as Drug Product.
With investments of 100 Million USD Shortly , it will produce drugs related to cancer, anemia and infertility.
Brand products
